Actinogen Historical Cash Flow

ACW Stock

0.03 0 3.85%

Analysis of Actinogen Medical cash flow over time is an excellent tool to project Actinogen Medical future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Total Cash From Financing Activities of 18.8 M or End Period Cash Flow of 5.5 M as it is a great indicator of Actinogen Medical ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Actinogen Medical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Actinogen Medical is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinogen Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Actinogen Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Actinogen balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Actinogen's non-liquid assets can be easily converted into cash.

Actinogen Medical Cash Flow Chart

At this time, Actinogen Medical's Capital Expenditures is comparatively stable compared to the past year. Total Cash From Financing Activities is likely to gain to about 18.8 M in 2024, despite the fact that Free Cash Flow is likely to grow to (16.1 M).

Capital Expenditures End Period Cash Flow Begin Period Cash Flow Change To Netincome Stock Based Compensation Change To Inventory

Capital Expenditures

Capital Expenditures are funds used by Actinogen Medical to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Actinogen Medical operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Change To Inventory

The increase or decrease in the amount of inventory a company has over a certain period.

Most accounts from Actinogen Medical's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Actinogen Medical current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinogen Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Actinogen Medical cash flow statement Correlations

	Capital Expenditures	End Period Cash Flow	Sale Purchase Of Stock	Change In Cash	Free Cash Flow	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Net Income	Change To Account Receivables	Change In Working Capital	Investments	Change To Operating Activities	Change To Netincome	Change To Liabilities	Stock Based Compensation	Change To Inventory	Net Borrowings	Issuance Of Capital Stock
Capital Expenditures		0.12	0.27	-0.61	-0.34	0.7	0.42	0.11	-0.5	0.0	0.01	0.18	0.11	0.39	0.09	-0.11	0.27	-0.35	-0.36
End Period Cash Flow	0.12		-0.06	0.44	-0.49	0.52	0.66	0.45	-0.63	-0.23	-0.18	0.55	-0.39	0.56	0.39	-0.14	0.26	-0.64	0.33
Sale Purchase Of Stock	0.27	-0.06		-0.24	-0.1	0.16	0.07	-0.33	-0.11	0.03	0.02	0.09	-0.2	-0.16	-0.4	-0.38	0.45	-0.11	-0.16
Change In Cash	-0.61	0.44	-0.24		0.1	-0.53	-0.11	-0.11	0.11	0.09	0.08	0.15	-0.4	0.0	-0.27	0.0	0.12	-0.07	0.31
Free Cash Flow	-0.34	-0.49	-0.1	0.1		-0.57	-0.53	-0.21	0.95	0.86	0.84	-0.49	-0.28	-0.8	-0.33	0.09	-0.25	0.59	-0.46
Begin Period Cash Flow	0.7	0.52	0.16	-0.53	-0.57		0.71	0.55	-0.7	-0.32	-0.26	0.37	0.02	0.53	0.62	-0.11	0.12	-0.53	0.02
Depreciation	0.42	0.66	0.07	-0.11	-0.53	0.71		0.2	-0.68	-0.21	-0.18	0.76	-0.21	0.42	0.43	-0.6	0.56	-0.8	0.24
Other Non Cash Items	0.11	0.45	-0.33	-0.11	-0.21	0.55	0.2		-0.31	-0.16	-0.1	-0.02	-0.1	0.48	0.76	0.41	-0.45	-0.14	0.16
Net Income	-0.5	-0.63	-0.11	0.11	0.95	-0.7	-0.68	-0.31		0.67	0.64	-0.6	-0.18	-0.85	-0.35	0.13	-0.34	0.72	-0.35
Change To Account Receivables	0.0	-0.23	0.03	0.09	0.86	-0.32	-0.21	-0.16	0.67		1.0	-0.13	-0.41	-0.64	-0.41	-0.09	0.1	0.18	-0.51
Change In Working Capital	0.01	-0.18	0.02	0.08	0.84	-0.26	-0.18	-0.1	0.64	1.0		-0.11	-0.41	-0.61	-0.35	-0.07	0.07	0.15	-0.51
Investments	0.18	0.55	0.09	0.15	-0.49	0.37	0.76	-0.02	-0.6	-0.13	-0.11		-0.16	0.23	-0.02	-0.61	0.78	-0.96	0.2
Change To Operating Activities	0.11	-0.39	-0.2	-0.4	-0.28	0.02	-0.21	-0.1	-0.18	-0.41	-0.41	-0.16		0.31	0.11	0.44	-0.38	0.22	-0.12
Change To Netincome	0.39	0.56	-0.16	0.0	-0.8	0.53	0.42	0.48	-0.85	-0.64	-0.61	0.23	0.31		0.48	0.25	-0.07	-0.36	0.29
Change To Liabilities	0.09	0.39	-0.4	-0.27	-0.33	0.62	0.43	0.76	-0.35	-0.41	-0.35	-0.02	0.11	0.48		0.16	-0.48	-0.08	0.3
Stock Based Compensation	-0.11	-0.14	-0.38	0.0	0.09	-0.11	-0.6	0.41	0.13	-0.09	-0.07	-0.61	0.44	0.25	0.16		-0.79	0.55	-0.07
Change To Inventory	0.27	0.26	0.45	0.12	-0.25	0.12	0.56	-0.45	-0.34	0.1	0.07	0.78	-0.38	-0.07	-0.48	-0.79		-0.74	0.01
Net Borrowings	-0.35	-0.64	-0.11	-0.07	0.59	-0.53	-0.8	-0.14	0.72	0.18	0.15	-0.96	0.22	-0.36	-0.08	0.55	-0.74		-0.27
Issuance Of Capital Stock	-0.36	0.33	-0.16	0.31	-0.46	0.02	0.24	0.16	-0.35	-0.51	-0.51	0.2	-0.12	0.29	0.3	-0.07	0.01	-0.27

Click cells to compare fundamentals

Actinogen Medical Account Relationship Matchups

Actinogen Medical cash flow statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Cash From Financing Activities	282.3K	10.1M	12.4M	824.6K	17.9M	18.8M
End Period Cash Flow	5.0M	13.4M	16.4M	8.5M	9.5M	5.5M
Sale Purchase Of Stock	(796.3K)	7.9M	(715.9K)	(831.3K)	(1.1M)	(1.0M)
Change In Cash	(2.6M)	8.4M	2.9M	(7.9M)	990.7K	1.0M
Free Cash Flow	(2.9M)	(1.7M)	(9.5M)	(8.7M)	(17.0M)	(16.1M)
Begin Period Cash Flow	7.6M	5.0M	13.4M	16.4M	8.5M	5.2M
Other Cashflows From Financing Activities	(77.7K)	635.9K	(71.2K)	(78.3K)	(91.7K)	(87.1K)
Depreciation	412.9K	386.7K	400.7K	405.6K	416.8K	244.7K
Other Non Cash Items	(822.4K)	1.8M	3.8M	2.3M	912.1K	957.7K
Total Cash From Operating Activities	(2.9M)	(1.7M)	(9.5M)	(8.7M)	(17.0M)	(16.1M)
Net Income	(5.3M)	(3.9M)	(9.5M)	(10.8M)	(13.0M)	(12.4M)
Change To Account Receivables	1.8M	1.5M	(2.4M)	(181.7K)	(5.2M)	(4.9M)
Change In Working Capital	1.9M	1.5M	(1.7M)	131.8K	(5.2M)	(5.0M)
Total Cashflows From Investing Activities	(22.8K)	(6.2K)	(2.9K)	(36.6K)	(42.1K)	(40.0K)
Investments	(22.8K)	(6.2K)	(2.9K)	(36.6K)	(8.2K)	(8.6K)
Change To Operating Activities	24.7K	(84.2K)	28.5K	62.4K	56.1K	58.9K
Change To Netincome	194.5K	289.3K	1.3M	1.5M	1.7M	1.8M
Change To Liabilities	75.7K	110.3K	688.8K	251.1K	288.8K	157.1K
Stock Based Compensation	194.5K	289.3K	1.3M	1.5M	1.3M	774.1K
Change To Inventory	(100.4K)	(26.1K)	(717.3K)	(313.5K)	(282.1K)	(296.2K)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Actinogen Stock Analysis

When running Actinogen Medical's price analysis, check to measure Actinogen Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actinogen Medical is operating at the current time. Most of Actinogen Medical's value examination focuses on studying past and present price action to predict the probability of Actinogen Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actinogen Medical's price. Additionally, you may evaluate how the addition of Actinogen Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC